专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2019090097A1 AMINO-POLYESTERS FOR DRUG DELIVERY 审中-公开
公开(公告)号：WO2019090097A1
公开(公告)日：2019-05-09
申请号：PCT/US2018/058985
申请日：2018-11-02
申请人： MASSACHUSETTS INSTITUTE OF TECHNOLOGY , POLITECNICO DI MILANO
发明人： KOWALSKI, Piotr S. , ANDERSON, Daniel Griffith , MOSCATELLI, Davide , CAPASSO PALMIERO, Umberto
IPC分类号： C07C211/13 , A61K39/00 , A61K9/00 , A61K47/34 , C07D471/04 , C08G73/02 , C08G73/06
CPC分类号： C08G63/912 , A61K9/0019 , A61K9/127 , A61K9/1271 , A61K9/5153 , A61K31/7105 , A61K47/34 , C07C211/13 , C07D471/04 , C08G73/02 , C08G73/06
摘要： Disclosed are methods, compositions, reagents, systems, and kits to prepare and utilize amino-polyesters (APEs). The APEs are shown to be effective biodegradable carriers for drug delivery applications.

2. 发明申请

WO2019071229A1 COMPOSITIONS, METHODS, SYSTEMS AND/OR KITS FOR PREVENTING AND/OR TREATING NEOPLASMS 审中-公开
公开(公告)号：WO2019071229A1
公开(公告)日：2019-04-11
申请号：PCT/US2018/054753
申请日：2018-10-05
申请人： RESEARCH CANCER INSTITUTE OF AMERICA
发明人： NEZAMI, Mohammed, Amin
IPC分类号： A61K31/353 , A61K36/82 , A61P35/04
CPC分类号： A61P35/04 , A61K9/0019 , A61K9/5146 , A61K9/5153 , A61K31/192 , A61K31/352 , A61K31/353 , A61K31/495 , A61K45/06 , A61K2300/00
摘要： Provided herein are compositions, methods, systems and/or kits for preventing and/or treating neoplasms using at least one modulator selected from quercetin, sodium phenyl butyrate and epigallocatechin-3-gallate in combination with one or more anti-cancer agents. The compositions, methods, systems and/or kits are used to prevent and/or treat neoplasms that are resistant to the one or more anti-cancer agents when administered alone. Also provided are nanoformulations based on nanoparticles comprising one or more anti-cancer agents and/or one or more modulators for preventing and/or treating neoplasms.

3. 发明申请

WO2018237004A1 SELECTIVE RARy LIGAND-LOADED NANOPARTICLES FOR MANIPULATION OF TARGETED BONE GROWTH 审中-公开
公开(公告)号：WO2018237004A1
公开(公告)日：2018-12-27
申请号：PCT/US2018/038504
申请日：2018-06-20
申请人： UNIVERSITY OF MARYLAND, BALTIMORE , CHILDREN'S HOSPITAL OF PHILADELPHIA
发明人： IWAMOTO, Masahiro , CHORNY, Michael
IPC分类号： A61K31/192 , A61K47/34 , A61K9/19
CPC分类号： A61K9/19 , A61K9/5153 , A61K9/5192 , A61K31/192 , A61K31/415 , A61K47/34 , A61P19/08
摘要： The invention relates to compositions and methods as part of a pharmacotherapeutic strategy that targets the endochondral ossification process in a pharmacologically selective and site-specific manner. A variety of orthopedic pathologies are caused by or associated with generalized or local dysregulation of endochondral ossification, for example trauma to the bone growth plate or diaphysis can cause a serious imbalance in bone growth, leading to progressive deformity that today can only be treated surgically. Dysregulated endochondral ossification is also behind heterotopic ossification, which arises in soft tissues and causes pain, decrease in mobility and other clinical problems. The invention therefore provides RARy agonist and antagonist nanoparticle compositions for treating abnormal endochondral ossification and bone growth that can deliver robust local therapeutic control over a particular long bone's growth with a long-lasting effect.

4. 发明申请

WO2018166502A1 一种水难溶/微溶性药物缓释组合物审中-公开
公开(公告)号：WO2018166502A1
公开(公告)日：2018-09-20
申请号：PCT/CN2018/079173
申请日：2018-03-15
申请人：广州帝奇医药技术有限公司
发明人：赖树挺 , 郑阳 , 曹付春 , 连远发 , 刘锋
IPC分类号： A61K9/52 , A61K47/10
CPC分类号： A61K9/0002 , A61K9/5146 , A61K9/5153
摘要：一种水难溶/微溶性药物缓释组合物，其包括两种以上释放行为不同的水难溶/微溶性药物缓释微球，缓释聚合物为聚丙交酯、丙交酯-乙交酯共聚物、它们与聚乙二醇的共聚物中的至少一种。

5. 发明申请

WO2018057199A1 COMPOSITIONS FOR ENHANCED UPTAKE BY MACROPHAGES AND METHODS OF USE THEREOF 审中-公开
标题翻译：用于增强巨噬细胞摄取的组合物及其使用方法
公开(公告)号：WO2018057199A1
公开(公告)日：2018-03-29
申请号：PCT/US2017/048015
申请日：2017-08-22
申请人： YALE UNIVERSITY , UNIVERSITY OF SOUTHERN CALIFORNIA
发明人： FAHMY, Tarek , TOWN, Terrence, C. , WEITZ, Tara, M.
IPC分类号： A61K9/51 , A61K9/00 , A61K47/02 , A61K9/127 , A61K49/18 , A61P29/00 , A61P37/00 , A61P35/00
CPC分类号： A61K9/5153 , A61K9/0019 , A61K9/127 , A61K9/1271 , A61K31/4439 , A61K47/02 , A61K47/6849 , A61K47/6937 , A61K49/1827 , A61P25/28
摘要： Negatively charged nanoparticulate compositions are used to deliver therapeutic, prophylactic or diagnostic agents to macrophages or other phagocytic cells in the brain and central nervous system. The negative charge of the nanoparticles increases circulation, increase internalization by macrophage or other phagocytic cells, increase release within the macrophage or other phagocytic cells, or a combination thereof, relative to charge-neutral or charge-positive nanoparticles.
摘要翻译：带负电荷的纳米颗粒组合物用于将治疗剂，预防剂或诊断剂递送至脑和中枢神经系统中的巨噬细胞或其他吞噬细胞。与电荷中性或电荷正性纳米颗粒相比，纳米颗粒的负电荷增加了循环，增加了巨噬细胞或其他吞噬细胞的内化，增加了巨噬细胞或其他吞噬细胞或其组合中的释放。

6. 发明申请

WO2018053300A1 BIODEGRADABLE POLYMERIC PARTICLES ENCAPSULATING AN ACTIVE AGENT, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF 审中-公开
标题翻译：包裹活性剂的生物可降解聚合物颗粒，药物组合物及其用途
公开(公告)号：WO2018053300A1
公开(公告)日：2018-03-22
申请号：PCT/US2017/051830
申请日：2017-09-15
申请人： AUBURN UNIVERSITY , ALTIMMUNE, INC.
发明人： DAVID, Allan E. , BAKER, Henry J. , JOHNSON, Aime K. , ROBERTS, Scot M. , VAN KAMPEN, Kent R. , SANGLE, Prachi
IPC分类号： A61K9/113 , A61K47/42
CPC分类号： A61K9/5036 , A61K9/0019 , A61K9/0095 , A61K9/19 , A61K9/5031 , A61K9/5153 , A61K39/12 , A61K39/145 , A61K39/235 , A61K2039/55555 , A61P31/16 , A61P31/20 , C12N2710/10034 , C12N2710/10343 , C12N2760/16034 , C12N2760/16071 , C12N2760/16134
摘要： Therapeutic or prophylactic compositions providing an active agent, such as an antigen or a vector that contains and expresses an antigen, encapsulated in or incorporated into a biodegradable polymeric particle are provided. The compositions can also provide an active agent that is not encapsulated in or incorporated into the biodegradable polymeric particle in order to provide an initial or prime delivery of the active agent. Particles or composites providing an active agent encapsulated by a first and second polymer are also provided, wherein polymers are distributed in a gradient from a core of the composite to a surface of the composite, and configured to provide a delayed release of the active agent by a period of 7 days to 6 months. Methods of producing composites are also provided. Pharmaceutical formulations providing a single dose composition are also provided, along with methods for administering the pharmaceutical compositions to a subject in need thereof a therapeutically effective amount of an active agent are provided.
摘要翻译：提供了包含或掺入生物可降解聚合物颗粒中的提供活性剂（例如抗原或包含和表达抗原的载体）的治疗性或预防性组合物。该组合物还可提供未被包封或结合到可生物降解聚合物颗粒中的活性剂，以提供活性剂的初始或主要递送。还提供了提供由第一和第二聚合物包封的活性剂的颗粒或复合物，其中聚合物以从复合物的核心到复合物的表面的梯度分布，并且被配置成通过以下方式提供活性剂的延迟释放：为期7天至6个月。还提供了生产复合材料的方法。还提供了提供单一剂量组合物的药物制剂，以及将药物组合物给予有需要的对象的方法，提供了治疗有效量的活性剂。

7. 发明申请

WO2018033744A1 CARRIER 审中-公开
公开(公告)号：WO2018033744A1
公开(公告)日：2018-02-22
申请号：PCT/GB2017/052440
申请日：2017-08-17
申请人： GLOBALACORN LTD. , TECHNICKÁ UNIVERZITA V LIBERCI , VÝZKUMNÝ ÚSTAV VETERINÁRNÍHO LÉKARSTVÍ , UNIVERZITA PALACKÉHO V OLOMOUCHI
发明人： MAŠEK, Josef , LUKÁC, Róbert , RAŠKA, Milan , KNÖTIGOVÁ, Pavlína Turánek , TURÁNEK, Jaroslav , LUBASOVÁ, Daniela , MILLER, Andrew David
IPC分类号： A61K9/70 , A61K9/127 , A61K9/51
CPC分类号： A61K9/006 , A61K9/1271 , A61K9/5153 , A61K9/7084
摘要： The present invention relates to a mucoadhesive carrier or drug delivery system, which comprises nanoscaffold having a nanofibrous layer with a thickness of from 0.1 to 1000 µm, carrying the active substance in the form of particles. The mucoadhesive layer, in at least a part of its surface, overlaps the nanoscaffold so that it can adhere to the mucosa. A process for its preparation (the nanofibres are formed by electrospinning) and its use for delivery of the vaccines and therapeutics to mucosal surfaces is also disclosed.
摘要翻译：本发明涉及粘膜粘附载体或药物递送系统，其包含纳米支架，所述纳米支架具有厚度为0.1-1000微米的纳米纤维层，其携带颗粒形式的活性物质。粘膜粘附层至少在其一部分表面上与纳米支架重叠，从而可粘附于粘膜。还公开了其制备方法（通过静电纺丝形成纳米纤维）及其用于将疫苗和治疗剂递送至粘膜表面的用途。

8. 发明申请

WO2018000082A2 ENCAPSULATION-FREE CONTROLLED PROTEIN RELEASE SYSTEM 审中-公开
标题翻译：无包膜控制的蛋白释放系统
公开(公告)号：WO2018000082A2
公开(公告)日：2018-01-04
申请号：PCT/CA2017/050615
申请日：2017-05-19
申请人： SHOICHET, Molly
发明人： SHOICHET, Molly , PAKULSKA, Malgosia M. , ELLIOTT DONAGHUE, Irja , OBERMEYER, Jaclyn M.
CPC分类号： A61K9/5153 , A61K9/06 , A61K9/146 , A61K38/00 , A61K38/1816 , A61K38/185 , A61K38/195 , A61K47/36 , A61K47/38
摘要： The present disclosure provides a delivery system for controlled protein release without encapsulation. Identical, burst-free, extended release profiles for three different protein therapeutics were obtained with and without encapsulation in PLGA nanoparticles embedded within a hydrogel. Using both positively and negatively charged proteins, it was shown that short-range electrostatic interactions between the proteins and the PLGA nanoparticles are the underlying mechanism for controlled release. Moreover, tunable release was demonstrated by modifying nanoparticle concentration, nanoparticle size, or environmental pH. Additionally, the utility of this system was demonstrated in vivo for BDNF delivery in a rat model of stroke. These new insights obviate the need for encapsulation and offer promising, translatable strategies for more effective delivery of therapeutic biomolecules.
摘要翻译：本公开提供了用于控制蛋白释放而不包封的递送系统。获得了三种不同的蛋白质治疗剂的相同的无爆发的延长释放曲线，其中包封和未包封在嵌入水凝胶内的PLGA纳米粒子中。使用正电荷和负电荷蛋白质，表明蛋白质和PLGA纳米粒子之间的短程静电相互作用是控制释放的基本机制。此外，通过改变纳米颗粒浓度，纳米颗粒尺寸或环境pH可证明可调释放。此外，该系统在中风大鼠模型中的BDNF递送的体内效用被证实。这些新的见解避免了封装的需要，并提供了有前途的，可转换的策略，以更有效地递送治疗性生物分子。

9. 发明申请

WO2017147240A1 HSP90 TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF 审中-公开
标题翻译： HSP90靶向的缀合物及其颗粒和组合物
公开(公告)号：WO2017147240A1
公开(公告)日：2017-08-31
申请号：PCT/US2017/019040
申请日：2017-02-23
申请人： TARVEDA THERAPEUTICS, INC.
发明人： SHINDE, Rajesh R. , BILODEAU, Mark T. , WOOSTER, Richard , KADIYALA, Sudhakar
IPC分类号： A61K49/00 , A61K47/48
CPC分类号： A61K47/545 , A61K9/5146 , A61K9/5153 , A61K31/437 , A61K47/64
摘要： Conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to an HSP90 targeting moiety via a linker have been designed. Nanoparticles and microparticles comprising such conjugates can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or other diseases.
摘要翻译：已经设计了通过接头连接到HSP90靶向部分的活性剂例如治疗剂，预防剂或诊断剂的偶联物。包含这种缀合物的纳米粒子和微粒可以提供活性剂的改善的空间递送和/或改善的生物分布。提供了制备缀合物，颗粒及其制剂的方法。提供将制剂给予有需要的受试者的方法，例如用于治疗或预防癌症或其他疾病。

10. 发明申请

WO2017138983A1 THERAPEUTIC NANOPARTICLES HAVING EGFR LIGANDS AND METHODS OF MAKING AND USING SAME 审中-公开
标题翻译：具有EGFR配体的治疗性纳米颗粒及其制备和使用方法
公开(公告)号：WO2017138983A1
公开(公告)日：2017-08-17
申请号：PCT/US2016/047807
申请日：2016-08-19
申请人： PFIZER INC.
发明人： ZALE, Stephen, E. , MCDONNELL, Kevin , HORHOTA, Allen
IPC分类号： A61K47/48 , A61K51/08 , A61K49/08
CPC分类号： A61K9/146 , A61K9/0019 , A61K9/5153 , A61K38/1709 , A61K47/34 , A61K47/48176 , A61K47/482 , A61K47/593 , A61K47/60 , A61K47/62 , A61K47/6937 , A61K2121/00
摘要： Provided herein in part is a therapeutic nanoparticle that includes a biocompatible polymer; a polymer -EGFR ligand conjugate, wherein the EGFR ligand is covalently bound directly or through a chemical linker to the polymer, and a therapeutic agent.
摘要翻译：本文中部分提供了包含生物相容性聚合物的治疗性纳米颗粒; 聚合物-EGFR配体缀合物，其中EGFR配体直接或通过化学接头共价结合至聚合物，和治疗剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式